Antibiotic Sensitivity of Proteus mirabilis Urinary Tract Infection in Patients with Urinary Calculi

Table 3

Annual and total sensitivity profiles based on antibiotic sensitivity trials of Proteus mirabilis isolates from urinary calculus patients during the 2019–2021 study period (%).

Antibiotic	2019 (n = 101)	2020 (n = 112)	2021 (n = 104)	2019–2021 (n = 317)	value
Meropenem	99 (98.0)	110 (98.2)	102 (98.1)	311 (98.1)	0.994
Imipenem	96 (95.1)	108 (96.4)	101 (97.1)	305 (96.2)	0.733
Levofloxacin	69 (68.3)	57 (50.8)	57 (54.8)	183 (57.7)	0.028
Cefuroxime	59 (58.4)	59 (52.7)	43 (41.4)	161 (50.8)	0.045
Cefoxitin	84 (83.2)	99 (88.4)	88 (84.6)	271 (85.5)	0.532
Ceftazidime	85 (84.2)	102 (91.1)	89 (85.6)	276 (87.1)	0.278
Ceftriaxone	66 (65.4)	73 (65.2)	57 (54.8)	196 (61.8)	0.198
Cefoperazone/Sulbactam	97 (96.0)	106 (94.6)	101 (97.1)	304 (95.9)	0.655
Cefepime	85 (84.2)	95 (84.8)	87 (83.7)	267 (84.2)	0.972
Amikacin	100 (98.6)	112 (100)	102 (98.1)	314 (99.1)	0.345
Piperacillin/Tazobactam	88 (87.1)	97 (86.6)	93 (89.4)	278 (87.7)	0.802
Sulfamethoxazole	32 (31.7)	43 (38.4)	32 (30.8)	107 (33.8)	0.430